Logo image of APVO

APTEVO THERAPEUTICS INC (APVO) Stock Fundamental Analysis

USA - NASDAQ:APVO - US03835L5049 - Common Stock

1.425 USD
0 (-0.35%)
Last: 11/6/2025, 11:28:03 AM
Fundamental Rating

2

Taking everything into account, APVO scores 2 out of 10 in our fundamental rating. APVO was compared to 534 industry peers in the Biotechnology industry. APVO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. APVO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

APVO had negative earnings in the past year.
APVO had a negative operating cash flow in the past year.
APVO had negative earnings in 4 of the past 5 years.
APVO had a negative operating cash flow in each of the past 5 years.
APVO Yearly Net Income VS EBIT VS OCF VS FCFAPVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of APVO (-153.77%) is worse than 85.96% of its industry peers.
With a Return On Equity value of -368.26%, APVO is not doing good in the industry: 74.34% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -153.77%
ROE -368.26%
ROIC N/A
ROA(3y)-66.85%
ROA(5y)-56.8%
ROE(3y)-200.85%
ROE(5y)-609.94%
ROIC(3y)N/A
ROIC(5y)N/A
APVO Yearly ROA, ROE, ROICAPVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

APVO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APVO Yearly Profit, Operating, Gross MarginsAPVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

APVO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, APVO has more shares outstanding
There is no outstanding debt for APVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
APVO Yearly Shares OutstandingAPVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500 1K 1.5K
APVO Yearly Total Debt VS Total AssetsAPVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

APVO has an Altman-Z score of -27.66. This is a bad value and indicates that APVO is not financially healthy and even has some risk of bankruptcy.
APVO has a Altman-Z score of -27.66. This is amonst the worse of the industry: APVO underperforms 88.20% of its industry peers.
There is no outstanding debt for APVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.66
ROIC/WACCN/A
WACCN/A
APVO Yearly LT Debt VS Equity VS FCFAPVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 2.27 indicates that APVO has no problem at all paying its short term obligations.
With a Current ratio value of 2.27, APVO is not doing good in the industry: 71.72% of the companies in the same industry are doing better.
APVO has a Quick Ratio of 2.27. This indicates that APVO is financially healthy and has no problem in meeting its short term obligations.
APVO has a worse Quick ratio (2.27) than 69.66% of its industry peers.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 2.27
APVO Yearly Current Assets VS Current LiabilitesAPVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

APVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.87%, which is quite impressive.
EPS 1Y (TTM)92.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, APVO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.87% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.86%
EPS Next 2Y41.4%
EPS Next 3Y25.98%
EPS Next 5Y14.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APVO Yearly Revenue VS EstimatesAPVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2027 2029 2030 2031 2032 20M 40M 60M
APVO Yearly EPS VS EstimatesAPVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500K -1M -1.5M -2M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

APVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year APVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APVO Price Earnings VS Forward Price EarningsAPVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APVO Per share dataAPVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K -1.5K -2K

4.3 Compensation for Growth

APVO's earnings are expected to grow with 25.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.4%
EPS Next 3Y25.98%

More info and screens

0

5. Dividend

5.1 Amount

APVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APTEVO THERAPEUTICS INC

NASDAQ:APVO (11/6/2025, 11:28:03 AM)

1.425

0 (-0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05
Earnings (Next)02-12 2026-02-12/amc
Inst Owners9.6%
Inst Owner Change0%
Ins Owners0%
Ins Owner Change0%
Market Cap4.69M
Revenue(TTM)N/A
Net Income(TTM)-24025000
Analysts82.86
Price Target428.4 (29963.16%)
Short Float %27.34%
Short Ratio0.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)43.94%
Min EPS beat(2)-2.23%
Max EPS beat(2)90.1%
EPS beat(4)2
Avg EPS beat(4)-192.04%
Min EPS beat(4)-942%
Max EPS beat(4)90.1%
EPS beat(8)6
Avg EPS beat(8)-70.99%
EPS beat(12)9
Avg EPS beat(12)-32.82%
EPS beat(16)12
Avg EPS beat(16)5.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)97.24%
EPS NY rev (1m)0%
EPS NY rev (3m)95.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-2098.8
EYN/A
EPS(NY)-7.57
Fwd EYN/A
FCF(TTM)-7.43
FCFYN/A
OCF(TTM)-7.43
OCFYN/A
SpS0
BVpS1.98
TBVpS1.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -153.77%
ROE -368.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.85%
ROA(5y)-56.8%
ROE(3y)-200.85%
ROE(5y)-609.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 2.27
Altman-Z -27.66
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.32%
EPS Next Y99.86%
EPS Next 2Y41.4%
EPS Next 3Y25.98%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-87.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.06%
OCF growth 3YN/A
OCF growth 5YN/A

APTEVO THERAPEUTICS INC / APVO FAQ

What is the ChartMill fundamental rating of APTEVO THERAPEUTICS INC (APVO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to APVO.


What is the valuation status for APVO stock?

ChartMill assigns a valuation rating of 1 / 10 to APTEVO THERAPEUTICS INC (APVO). This can be considered as Overvalued.


How profitable is APTEVO THERAPEUTICS INC (APVO) stock?

APTEVO THERAPEUTICS INC (APVO) has a profitability rating of 0 / 10.


How financially healthy is APTEVO THERAPEUTICS INC?

The financial health rating of APTEVO THERAPEUTICS INC (APVO) is 5 / 10.